Defensin susceptibility and colonization in the mouse model of AJ100, a polymyxin B-resistant, Brucella abortus RB51 isolate.

Current Microbiology
S M HallingS C Olsen

Abstract

Intracellular pathogens selected for increased susceptibility to polycations are commonly attenuated, yet the effect of decreased susceptibility to polycations on pathogenicity has not been researched. The polymyxin-resistant mutant Brucella abortus AJ100 was characterized by comparing its susceptibility to the polycationic antibiotic polymyxin B, defensins, and lactoferricin, and its colonization and clearance in the mouse model to the parent strain RB51. MIC (minimum inhibitory concentration) values determined by Etest for AJ100 and RB51 were 1.5 and 0.25 mug/ml, respectively. Though AJ100 is less susceptible to polymyxin B than RB51, it was more susceptible than its parent strain to the cationic defensins melittin, magainin 2, and cecropin P1. In the mouse model, initial colonization of the spleen was lower for AJ100 than RB51, and the rate of clearance from the spleen was faster for AJ100 than RB51. However, initial colonization and clearance rates of AJ100 from the liver were indistinguishable from those of RB51. This study suggests that the susceptibility profile of Brucella to polycationic defensins rather than polymyxin B may be indicative of differential survival in the spleen and liver in the mouse and is indicative o...Continue Reading

References

Sep 1, 1992·Microbiological Reviews·M Vaara
Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·E A GroismanF Heffron
Jul 1, 1991·Veterinary Microbiology·G G SchurigN Sriranganathan
Aug 1, 1995·Infection and Immunity·G Martínez de TejadaI Moriyón
Mar 1, 1993·Microbial Pathogenesis·F M TatumS M Halling
Feb 1, 1997·Comparative Immunology, Microbiology and Infectious Diseases·M G StevensJ E Mayfield
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·R E Hancock, M G Scott
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·C Guzman-VerriI Lopez-Goni
Sep 26, 2003·Molecular Microbiology·Martin W BaderSamuel I Miller
Feb 8, 2005·Current Opinion in Microbiology·Nicolas LapaqueJean-Pierre Gorvel
Sep 26, 2008·Comparative Immunology, Microbiology and Infectious Diseases·Allen E Jensen, Shirley M Halling

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

Etest

Related Concepts

Related Feeds

Brucellosis (ASM)

Brucellosis is a bacterial infection caused by members of the genus brucella and remains one of the world's major zoonotic diseases. Discover the latest research on Brucellosis here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Brucellosis

Brucellosis is a bacterial infection caused by members of the genus brucella and remains one of the world's major zoonotic diseases. Discover the latest research on Brucellosis here.